FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns the use of fusion protein in treatment and/or prevention of infection with hepatitis B virus, where the specified fusion protein contains PreS polypeptide of the hepatitis B virus fused with a peptide consisting of the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4.
EFFECT: invention provides the formation of PreS-specific IgG to a much greater extent than PreS alone or other fusion proteins also containing PreS fused to various peptides, in particular PreS-F1, PreS-F2 or PreS-F4.
7 cl, 8 ex, 8 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT AND PREVENTION OF ALLERGY TO HOUSE DUST MITES | 2019 |
|
RU2815386C2 |
| COMPOSITIONS AND METHODS OF TREATING AND PREVENTING HEPATITIS B AND D | 2021 |
|
RU2812764C1 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
